Konstantinos Gkirkas

Athens, ESYE31, Greece

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Gilteritinib for Prevention of Post-transplant Relapse in Patients With Acute Myeloid Leukemia and FLT3-ITD Mutation: Real-Life Data from Two Centers.

Gilteritinib for Prevention of Post-transplant Relapse in Patients With Acute Myeloid Leukemia and FLT3-ITD Mutation: Real-Life Data from Two Centers.

Journal: Transplantation and cellular therapy

Published: February 05, 2026

Real-World Outcomes in NPM1-Mutated Acute Myeloid Leukemia: The Impact of Measurable Residual Disease on Disease Relapse.

Real-World Outcomes in NPM1-Mutated Acute Myeloid Leukemia: The Impact of Measurable Residual Disease on Disease Relapse.

Journal: American journal of hematology

Published: January 30, 2026

Rectal Colonization with Multidrug-Resistant Organisms and Subsequent Bloodstream Infections in Hematological Patients Undergoing Cellular Therapies.

Rectal Colonization with Multidrug-Resistant Organisms and Subsequent Bloodstream Infections in Hematological Patients Undergoing Cellular Therapies.

Journal: Transplantation and cellular therapy

Published: January 09, 2026

Low-dose post-transplant cyclophosphamide in combination with low-dose alemtuzumab for graft-versus-host-disease prevention in mismatched unrelated allogeneic stem cell transplantation is associated with improved outcomes and reduced toxicity.

Low-dose post-transplant cyclophosphamide in combination with low-dose alemtuzumab for graft-versus-host-disease prevention in mismatched unrelated allogeneic stem cell transplantation is associated with improved outcomes and reduced toxicity.

Journal: Bone marrow transplantation

Published: August 16, 2025

The Prognostic Impact of Additional Molecular and Cytogenetic Abnormalities on AML Patients with NPM1- and/or FLT3-ITD Mutations Receiving Intensive Chemotherapy: Real-World Data from the Greek Registry.

The Prognostic Impact of Additional Molecular and Cytogenetic Abnormalities on AML Patients with NPM1- and/or FLT3-ITD Mutations Receiving Intensive Chemotherapy: Real-World Data from the Greek Registry.

Journal: Cancers

Published: January 02, 2025

Management strategies for CAR-T cell therapy-related toxicities: results from a survey in Greece.

Management strategies for CAR-T cell therapy-related toxicities: results from a survey in Greece.

Journal: Frontiers in medicine

Published: December 31, 2024

EASIX and m-EASIX predict severe cytokine release syndrome and overall survival after CAR T-cell therapy.

EASIX and m-EASIX predict severe cytokine release syndrome and overall survival after CAR T-cell therapy.

Journal: Blood vessels, thrombosis & hemostasis

Published: March 13, 2024

Endothelial Injury Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation: Angiopetin-2 as a Novel Predictor of the Outcome and the Role of Functional Autoantibodies against Angiotensin II Type 1 and Endothelin A Receptor.

Endothelial Injury Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation: Angiopetin-2 as a Novel Predictor of the Outcome and the Role of Functional Autoantibodies against Angiotensin II Type 1 and Endothelin A Receptor.

Journal: International journal of molecular sciences

Published: February 27, 2023

Solid tumor transmission from donor to recipient after allogeneic stem cell transplantation: it is rare but it happens!

Solid tumor transmission from donor to recipient after allogeneic stem cell transplantation: it is rare but it happens!

Journal: Blood transfusion = Trasfusione del sangue

Published: November 13, 2022

Repetitively Administered Low-Dose Donor Lymphocyte Infusion for Prevention of Relapse after Allogeneic Stem Cell Transplantation in Patients with High-Risk Acute Leukemia.

Repetitively Administered Low-Dose Donor Lymphocyte Infusion for Prevention of Relapse after Allogeneic Stem Cell Transplantation in Patients with High-Risk Acute Leukemia.

Journal: Cancers

Published: May 10, 2021

Allogeneic Stem Cell Transplantation with a Novel Reduced Intensity Conditioning Regimen for the Treatment of Patients with Primary Cutaneous T-cell Lymphomas.

Allogeneic Stem Cell Transplantation with a Novel Reduced Intensity Conditioning Regimen for the Treatment of Patients with Primary Cutaneous T-cell Lymphomas.

Journal: Clinical hematology international

Published: March 27, 2021

Extramedullary leukemia relapse after allogeneic stem cell transplantation: a novel mechanism of immune escape?

Extramedullary leukemia relapse after allogeneic stem cell transplantation: a novel mechanism of immune escape?

Journal: Immunotherapy

Published: May 22, 2020

Showing 1-12 of 27

Last Updated: 09/26/2026